Statements (67)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Cephalon
|
| gptkbp:activities |
non-nucleoside reverse transcriptase inhibitor
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Edurant
|
| gptkbp:can_be_used_with |
gptkb:tenofovir
gptkb:emtricitabine |
| gptkbp:class |
non-nucleoside reverse transcriptase inhibitors
|
| gptkbp:clinical_trial |
gptkb:various_countries
pharmaceutical companies Phase III HIV-1 infection |
| gptkbp:composed_of |
synthetic organic compound
|
| gptkbp:contraindication |
severe liver disease
hypersensitivity to rilpivirine |
| gptkbp:developed_by |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
long-term therapy possible
|
| gptkbp:education |
importance of adherence
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
fixed-dose combination
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rilpivirine
|
| gptkbp:ingredients |
C22 H22 N6 O2
|
| gptkbp:interacts_with |
other antiretroviral drugs
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
effective in treatment-experienced patients
effective in treatment-naive patients |
| gptkbp:is_used_for |
treatment of HIV
|
| gptkbp:lifespan |
45 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Edurant
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
highly protein bound
inhibits HIV replication |
| gptkbp:population |
adults and adolescents
|
| gptkbp:provides_information_on |
once daily
HIV treatment guidelines recommended for first-line therapy |
| gptkbp:regulatory_compliance |
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency |
| gptkbp:research |
clinical trials
|
| gptkbp:research_areas |
HIV treatment
|
| gptkbp:research_focus |
HIV resistance patterns
|
| gptkbp:safety_features |
liver function tests
generally well tolerated |
| gptkbp:side_effect |
gptkb:historical_event
gptkb:lipodystrophy fatigue nausea rash insomnia liver enzyme elevation immune reconstitution inflammatory syndrome |
| gptkbp:social_structure |
pyrimidine derivative
|
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
HIV reverse transcriptase
|
| gptkbp:treatment |
improved quality of life
viral load reduction part of combination therapy improved C D4 count sustained viral suppression |
| gptkbp:type_of |
369726-12-0
|
| gptkbp:type_of_care |
important for efficacy
|